Singapore, 13 March 2018 – Julian Mark Andriesz, CEO of Verita Healthcare Group Limited, has been appointed President of the Cancer-Aid Foundation, a not-for-profit organisation duly registered under Swiss Foundation Law for the Supervision of Foundations in Switzerland.

BACKGROUND

The Cancer-Aid-Foundation is an international, neutral and independent organization that focuses on cancer research and has the goal of supporting new ways of improving diagnostic, preventive and therapeutic medical procedures. In order to find new therapeutic applications, the Cancer Aid Foundation supports universities and research centres worldwide.

The focus of these sophisticated therapeutic approaches that stem from areas of cancer molecular diagnostics, oncology and the conventional and complementary medicine, lies in looking for technology that demonstrates minimal side effects while having a low effect in terms of the patient’s quality of life. Only study projects are supported which have clear clinical benefits for cancer patients. This has to be proven accordingly during pre-assessments.

Julian Andriesz commented, “I am honoured to be able to contribute to the noble work of the Cancer-Aid Foundation and to expand its collaborations with top universities and research institutes around the world for the ultimate benefit of cancer suffers”.

01

Verita Founder and CEO Appointed President of Switzerland’s Cancer-aid Foundation

July 18, 2018

Singapore, 13 March 2018 – Julian Mark Andriesz, CEO of Verita Healthcare Group Limited, has been appointed President of the Cancer-Aid Foundation, a not-for-profit organisation duly registered under Swiss Foundation Law for the Supervision of Foundations in Switzerland.

BACKGROUND

The Cancer-Aid-Foundation is an international, neutral and independent organization that focuses on cancer research and has the goal of supporting new ways of improving diagnostic, preventive and therapeutic medical procedures. In order to find new therapeutic applications, the Cancer Aid Foundation supports universities and research centres worldwide.

The focus of these sophisticated therapeutic approaches that stem from areas of cancer molecular diagnostics, oncology and the conventional and complementary medicine, lies in looking for technology that demonstrates minimal side effects while having a low effect in terms of the patient’s quality of life. Only study projects are supported which have clear clinical benefits for cancer patients. This has to be proven accordingly during pre-assessments.

Julian Andriesz commented, “I am honoured to be able to contribute to the noble work of the Cancer-Aid Foundation and to expand its collaborations with top universities and research institutes around the world for the ultimate benefit of cancer suffers”.